Wanfu Lin

524 total citations
24 papers, 403 citations indexed

About

Wanfu Lin is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, Wanfu Lin has authored 24 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Immunology. Recurrent topics in Wanfu Lin's work include Immune cells in cancer (4 papers), Extracellular vesicles in disease (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Wanfu Lin is often cited by papers focused on Immune cells in cancer (4 papers), Extracellular vesicles in disease (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Wanfu Lin collaborates with scholars based in China and Taiwan. Wanfu Lin's co-authors include Changquan Ling, Binbin Cheng, Shufang Liang, Chen Wang, Shu Li, Huan Wang, Juan Du, Jiaying Yuan, Zifei Yin and Hetong Zhao and has published in prestigious journals such as Scientific Reports, Journal of Ethnopharmacology and Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

In The Last Decade

Wanfu Lin

22 papers receiving 401 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wanfu Lin China 12 175 109 67 62 52 24 403
Qin Dong China 12 269 1.5× 122 1.1× 74 1.1× 43 0.7× 34 0.7× 35 499
Rongli You China 7 278 1.6× 67 0.6× 67 1.0× 43 0.7× 29 0.6× 16 415
Linan Zhao China 11 201 1.1× 58 0.5× 65 1.0× 57 0.9× 26 0.5× 25 495
Zhenyu Zhou China 10 190 1.1× 99 0.9× 43 0.6× 47 0.8× 32 0.6× 14 333
Deok Yong Sim South Korea 15 332 1.9× 123 1.1× 100 1.5× 57 0.9× 22 0.4× 39 497
Weili Min China 17 299 1.7× 110 1.0× 132 2.0× 45 0.7× 41 0.8× 26 591
Mi‐Hyoung Kim South Korea 12 302 1.7× 61 0.6× 80 1.2× 113 1.8× 61 1.2× 15 574
Rongling Zhong China 11 208 1.2× 47 0.4× 62 0.9× 46 0.7× 45 0.9× 21 411
Ji Eon Park South Korea 13 281 1.6× 100 0.9× 75 1.1× 53 0.9× 22 0.4× 33 425

Countries citing papers authored by Wanfu Lin

Since Specialization
Citations

This map shows the geographic impact of Wanfu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanfu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanfu Lin more than expected).

Fields of papers citing papers by Wanfu Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanfu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanfu Lin. The network helps show where Wanfu Lin may publish in the future.

Co-authorship network of co-authors of Wanfu Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Wanfu Lin. A scholar is included among the top collaborators of Wanfu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanfu Lin. Wanfu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liang, Shufang, Maoyong Fu, Yehui Shi, et al.. (2025). Arsenic trioxide enhances the inhibitory effect of lenvatinib on hepatocellular carcinoma through HMOX1-mediated ferroptosis. International Immunopharmacology. 167. 115656–115656.
3.
4.
Zhang, Jinbo, Yuqian Wang, Shufang Liang, et al.. (2024). Jiedu recipe, a compound Chinese herbal medicine, suppresses hepatocellular carcinoma metastasis by inhibiting the release of tumor-derived exosomes in a hypoxic microenvironment. Journal of Integrative Medicine. 22(6). 696–708. 10 indexed citations
5.
Yuan, Jiaying, et al.. (2024). Bioactive sphingolipids as emerging targets for signal transduction in cancer development. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(5). 189176–189176. 11 indexed citations
6.
Liang, Shufang, Mingming Jin, Shu Li, et al.. (2023). Oleanolic acid inhibits hypoxic tumor-derived exosomes-induced premetastatic niche formation in hepatocellular carcinoma by targeting ERK1/2-NFκB signaling. Phytomedicine. 126. 155208–155208. 10 indexed citations
7.
Liang, Shufang, Wanfu Lin, Shu Li, et al.. (2023). Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-κB pathway. International Journal of Biological Sciences. 19(15). 4744–4762. 41 indexed citations
8.
Wang, Yuyao, et al.. (2023). The therapeutic principle of combined clearing heat and resolving toxin plus TACE on primary liver cancer: A systematic review and meta-analysis. Journal of Ethnopharmacology. 319(Pt 1). 117072–117072. 1 indexed citations
9.
Lin, Wanfu, Huan Wang, Shufang Liang, et al.. (2021). Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Evidence-based Complementary and Alternative Medicine. 2021. 1–10. 12 indexed citations
10.
Lin, Wanfu, Shu Li, Shufang Liang, et al.. (2021). UDCA Inhibits Hypoxic Hepatocellular Carcinoma Cell–Induced Angiogenesis Through Suppressing HIF-1α/VEGF/IL-8 Intercellular Signaling. Frontiers in Pharmacology. 12. 755394–755394. 22 indexed citations
11.
Lin, Wanfu, Zifei Yin, Yong Zou, et al.. (2019). Melittin Inhibits Hypoxia-Induced Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition through Suppression of HIF-1α/Akt Pathway in Liver Cancer. Evidence-based Complementary and Alternative Medicine. 2019. 1–10. 28 indexed citations
12.
Lin, Wanfu, Qing-Hui Zhou, Huan Wang, et al.. (2019). <p>Efficacy of complementary and integrative medicine on health-related quality of life in cancer patients: a systematic review and meta-analysis</p>. Cancer Management and Research. Volume 11. 6663–6680. 30 indexed citations
13.
Liang, Shufang, Yong Zou, Xiaolin Liu, et al.. (2018). The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways. Evidence-based Complementary and Alternative Medicine. 2018(1). 5629304–5629304. 13 indexed citations
14.
Lin, Wanfu, et al.. (2018). Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice. 2018. 1–10. 32 indexed citations
15.
16.
Liu, Dong, Binbin Cheng, Wanfu Lin, et al.. (2018). Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. Oncology Reports. 40(4). 2206–2214. 25 indexed citations
17.
Lin, Wanfu, et al.. (2017). Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment. Journal of Integrative Medicine. 15(4). 282–287. 35 indexed citations
18.
Lin, Wanfu, et al.. (2016). Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo. Oncology Reports. 36(2). 961–967. 66 indexed citations
19.
Lin, Wanfu, Shufang Liang, Dong Liu, et al.. (2016). Emodin inhibits migration and invasion of MHCC-97H human hepatocellular carcinoma cells. Experimental and Therapeutic Medicine. 12(5). 3369–3374. 20 indexed citations
20.
Lin, Wanfu, Chen Wang, & Changquan Ling. (2015). Research progress in anti-tumor effect of emodin. China Journal of Chinese Materia Medica. 40(20). 3937–40. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qin Dong Breakdown of academic impact, for papers by Rongli You Breakdown of academic impact, for papers by Linan Zhao Breakdown of academic impact, for papers by Zhenyu Zhou Breakdown of academic impact, for papers by Deok Yong Sim Breakdown of academic impact, for papers by Weili Min Breakdown of academic impact, for papers by Mi‐Hyoung Kim Breakdown of academic impact, for papers by Rongling Zhong Breakdown of academic impact, for papers by Ji Eon Park
Rankless by CCL
2026